Copyright
©The Author(s) 2023.
World J Cardiol. Jul 26, 2023; 15(7): 328-341
Published online Jul 26, 2023. doi: 10.4330/wjc.v15.i7.328
Published online Jul 26, 2023. doi: 10.4330/wjc.v15.i7.328
Figure 1 Pathophysiology of non-alcoholic fatty liver disease and heart failure with reduced ejection fraction.
LDL-c: Low-density lipoprotein-cholesterol; HDL-c: High-density lipoprotein-cholesterol; Hs-CRP: High-sensitivity C-reactive protein; ROS: Reactive oxygen species; FGF: Fibroblast growth factor; IL: Interleukin; PAI-1: Plasminogen activator inhibitor type 1; AF: Atrial fibrillation; RAAS: Renin angiotensin aldosterone system.
- Citation: Arriola-Montenegro J, Beas R, Cerna-Viacava R, Chaponan-Lavalle A, Hernandez Randich K, Chambergo-Michilot D, Flores Sanga H, Mutirangura P. Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease. World J Cardiol 2023; 15(7): 328-341
- URL: https://www.wjgnet.com/1949-8462/full/v15/i7/328.htm
- DOI: https://dx.doi.org/10.4330/wjc.v15.i7.328